Topical nonsteroidal anti-inflammatory drugs for osteoarthritis

Postgraduate Medicine

Volumn 122, Issue 6, 2010, Pages 98-106

  Richard Barthel, H ^a   Axford Gatley, Robert A ^b  

^a Rheumatology   (United States)

^b Clinical Content and Editorial Services   (United States)

Author keywords

Adverse events; Diclofenac; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Topical application

Indexed keywords

CELECOXIB; DICLOFENAC; DICLOFENAC DIETHYLAMINE; DIMETHYL SULFOXIDE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PLACEBO;

ANALGESIA; ANALGESIC ACTIVITY; APPLICATION SITE DERMATITIS; APPLICATION SITE REACTION; ARTICLE; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; KNEE OSTEOARTHRITIS; LOW DRUG DOSE; OSTEOARTHRITIS; SYSTEMATIC REVIEW; AGED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HAND JOINT; HOSPITALIZATION; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HAND JOINTS; HUMANS; MALE; OSTEOARTHRITIS; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 79952199947     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.11.2227     Document Type: Article

References (50)

1. Centers for Disease Control and Prevention. Prevalence of self-reported arthritis or chronic joint symptoms among adults-United States, 2001. MMWR Wkly. 2002;51(42):948-950.
2. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol. 2006;20(1):3-25.
3. Consumer Health Sciences. The Osteoarthritis Market: US Core Therapeutic Report. Princeton, NJ: Consumer Health Sciences; 2008.
4. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;331(7528):1310-1316.
5. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63(7):759-766.
6. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366.
7. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol. 1991;31(7):588-598.
8. Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531-539.
9. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346.
10. National Collaborating Centre for Chronic Conditions. Osteoarthritis: The Care and Management of Osteoarthritis in Adults. London, UK: Royal College of Physicians; 2008.
11. Mason L, Moore RA, Edwards JE, McQuay HJ, Derry S, Wiffen PJ. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ. 2004;328(7446):995.
12. Furst DE. Are there differences among nonsteroidal anti-inflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1994;37(1):1-9.
13. Cordero JA, Camacho M, Obach R, Domenech J, Vila L. In vitro based index of topical anti-inflammatory activity to compare a series of NSAIDs. Eur J Pharm Biopharm. 2001;51(2):135-142.
14. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81s-110s.
15. Kienzler J, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol New Drugs. 2010;50(1):50-61.
16. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69(1):180-186.
17. Barthel HR, Haselwood D, Longley S 3rd, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009;39(3):203-212.
18. Gondalf-Zink B, Gronwald U. Active substance concentration in articular and periarticular tissues of the knee joint after cutaneous application of diclofenac-diethylammonium emulgel. Akt Rheumatol. 1996;21:298-304.
19. Riess W, Schmid K, Botta L, et al. The percutaneous absorption of diclofenac. Arzneimittelforschung. 1986;36(7):1092-1096.
20. Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomized controlled trial. Ann Rheum Dis. 2007;66(9):1178-1183.
21. Bruhlmann P, de Vathaire F, Dreiser RL, Michel BA. Short-term treatment with topical diclofenac epolamine plaster in patients with symptomatic knee osteoarthritis: pooled analysis of two randomized clinical studies. Curr Med Res Opin. 2006;22(12):2429-2438.
22. Baraf HS, Gold MS, Clark MB, Altman RD. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial. Phys Sportsmed. 2010;38(2):19-28.
23. Niethard FU, Gold MS, Solomon GS, et al. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol. 2005;32(12):2384-2392.
24. Grace D, Rogers J, Skeith K, Anderson K. Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol. 1999;26(12):2659-2663.
25. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomized controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord. 2005;6:44.
26. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004;164(18):2017-2023.
27. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238-245.
28. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31(10):2002-2012.
29. Cross PL, Ashby D, Harding G, et al. TOIB Study Team. TOIB Study. Are topical or oral ibuprofen equally effective for the treatment of chronic knee pain presenting in primary care: a randomized controlled trial with patient preference study. [ISRCTN79353052]. BMC Musculoskelet Disord. 2005;6:55.
30. Kozanoglu E, Basaran S, Guzel R, Guler-Uysal F. Short term efficacy of ibuprofen phonophoresis versus continuous ultrasound therapy in knee osteoarthritis. Swiss Med Wkly. 2003;133(23-24):333-338.
31. Trnavsky K, Fischer M, Vogtle-Junkert U, Schreyger F. Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis. Results of a randomized, double-blind, placebo-controlled study. J Rheumatol. 2004;31(3):565-572.
32. Underwood M, Ashby D, Carnes D, et al. Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. Health Technol Assess. 2008;12(22):iii-iv.
33. Altman RD, Dreiser RL, Fisher CL, Chase WF, Dreher DS, Zacher J. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(9):1991-1999.
34. Zacher J, Burger K, Farber L, et al. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden's and/or Bouchard's nodes). Double-blind, controlled, randomized study. Aktuel Rheumatology. 2001;26:7-14.
35. Widrig R, Suter A, Saller R, Melzer J. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomized, double-blind study. Rheumatol Int. 2007;27(6):585-591.
36. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18(4):476-499.
37. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis. 2005;64(1):29-33.
38. Barthel HR, Peniston JH, Clark MB, Gold MS, Altman RD. Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis. Arthritis Res Ther. 2010;12(1):R7.
39. Singh G, Fort JG, Goldstein JL, et al; SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119(3):255-266.
40. Niculescu L, Li C, Huang J, Mallen S. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2009;25(3):729-740.
41. Moore RA, Derry S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7(3):R644-R665.
42. Gloth FM, Petruschke RA, Gold MS, Wieman MS. Safety and efficacy of diclofenac sodium 1% gel for knee osteoarthritis in patients with comorbidities. Poster presented at: American Pain Society Annual Scientific Meeting; May 6-8, 2010; Baltimore, MD.
43. Voltaren® Gel 1% (diclofenac sodium topical gel) [package insert]. Parsippany, NJ: Novartis Consumer Health, Inc; 2009.
44. PENNSAID® (diclofenac sodium topical solution) [package insert]. Varennes, Quebec, Canada: Nuvo Manufacturing; 2010.
45. Sandelin J, Harilainen A, Crone H, Hamberg P, Forsskahl B, Tamelander G. Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing eltenac with oral diclofenac and placebo gel. Scand J Rheumatol. 1997;26(4):287-292.
46. Dickson DJ. A double-blind evaluation of topical piroxicam gel with oral ibuprofen in osteoarthritis of the knee. Curr Ther Res Clin Exp. 1991;49(2):199-207.
47. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(3):377-388.
48. American Academy of Orthopaedic Surgeons. Treatment of Osteoarthritis of the Knee (Non-Arthroplasty). Rosemont, IL: American Academy of Orthopaedic Surgeons; December 6, 2008.
49. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 2000;7(3):159-175.
50. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99(1):91-98.